Neuroscience
Neurotransmitters
Chemical messengers that carry signals across synapses — dopamine, serotonin, GABA, more
Neurotransmitters are signaling molecules released from a presynaptic neuron's axon terminal that bind receptors on the postsynaptic cell, triggering excitation, inhibition, or modulation. Otto Loewi's 1921 frog-heart experiment first demonstrated chemical neurotransmission (acetylcholine). About 100 are known. Major small-molecule transmitters: glutamate (main excitatory), GABA (main inhibitory), acetylcholine, dopamine, norepinephrine, serotonin, histamine. Plus neuropeptides (endorphins, oxytocin, substance P) and gases (nitric oxide). Each operates through specific receptor families with distinct pharmacology. Many psychiatric drugs target neurotransmitter systems — SSRIs raise serotonin availability, antipsychotics block dopamine D2 receptors, benzodiazepines enhance GABA-A. Popular framings ("low serotonin causes depression") oversimplify; transmitter systems modulate networks, not single moods.
- First identifiedAcetylcholine (Otto Loewi 1921, Nobel 1936)
- Major excitatoryGlutamate (~80% of brain synapses)
- Major inhibitoryGABA
- MonoaminesDopamine, norepinephrine, serotonin
- NeuropeptidesEndorphins, oxytocin, substance P
- Drug classesSSRIs, antipsychotics, benzodiazepines, opioids
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
Why neurotransmitters matter
- Psychiatry. Drug selection rests on which transmitter system is targeted.
- Neurology. Parkinson's, Alzheimer's, epilepsy all involve specific transmitter dysfunctions.
- Pain medicine. Opioid receptors, NMDA antagonists, serotonin-norepinephrine modulators all relevant.
- Addiction medicine. Most addictive drugs hijack dopamine, GABA, or opioid systems.
- Sleep and circadian medicine. Adenosine, GABA, melatonin, orexin all play distinct roles.
- Drug development. Receptor subtype specificity drives next-generation medications.
- Public understanding. Patients deserve accurate models, not "chemical imbalance" oversimplification.
Common misconceptions
- One transmitter, one mood. No transmitter maps cleanly to a single emotion or function.
- Dopamine is the pleasure molecule. It signals prediction error and motivation, not hedonic pleasure.
- Low serotonin causes depression. Direct evidence is weak; modern theories are circuit-based.
- SSRIs work in days. Onset typically takes weeks despite immediate transmitter changes.
- More transmitter is always better. Excitotoxicity from glutamate, dyskinesias from dopamine show otherwise.
- Neurotransmitter and hormone are interchangeable. They differ in distance, timing, and target.
Frequently asked questions
How does synaptic transmission work?
Action potential reaches the axon terminal. Voltage-gated calcium channels open. Calcium influx triggers vesicles containing neurotransmitter to fuse with the presynaptic membrane and release contents into the synaptic cleft (~20-40 nm). Transmitter diffuses across, binds postsynaptic receptors, opening ion channels (ionotropic) or activating signaling cascades (metabotropic). Action terminates via reuptake, enzymatic breakdown, or diffusion. The whole sequence runs in under a millisecond.
What does dopamine do?
Multiple roles, depending on circuit. Mesolimbic (VTA → nucleus accumbens) — reward prediction error, motivation, reinforcement learning. Mesocortical (VTA → prefrontal cortex) — working memory, executive function. Nigrostriatal (substantia nigra → striatum) — voluntary movement; degeneration causes Parkinson's. Tuberoinfundibular — inhibits prolactin. The "pleasure molecule" framing is wrong; Schultz's monkey work showed dopamine signals prediction error, not pleasure itself.
What does serotonin do?
Originating in raphe nuclei, projects throughout brain. Modulates mood, sleep, appetite, aggression, sexual function, and gut motility (90% of body's serotonin is in the gut). SSRIs (fluoxetine, sertraline) increase synaptic availability by blocking reuptake. The simple "low serotonin = depression" hypothesis (popularized in the 1990s) is unsupported by direct evidence; recent reviews (Moncrieff et al. 2022) sparked debate. SSRIs help many patients, but the mechanism is more complex than a deficiency model.
What is GABA?
Gamma-aminobutyric acid. Main inhibitory transmitter. GABA-A receptors are ligand-gated chloride channels — opening hyperpolarizes the neuron, reducing firing. Targets of major drug classes. Benzodiazepines (alprazolam, diazepam) potentiate GABA-A — anxiolytic, sedative. Alcohol enhances GABA-A among many effects. Barbiturates do the same more strongly and lethally. GABAergic dysfunction implicated in epilepsy, anxiety disorders, schizophrenia.
What about glutamate?
Main excitatory transmitter. Binds AMPA receptors (fast excitation) and NMDA receptors (slower, calcium-permeable, central to LTP and learning). Excessive glutamate causes excitotoxicity — neuronal death from calcium overload, implicated in stroke, traumatic brain injury, ALS. Ketamine and PCP are NMDA antagonists; ketamine's rapid antidepressant effect (FDA-approved esketamine 2019) reshaped depression research toward glutamatergic models.
What's the difference from hormones?
Both are signaling molecules, but they differ in scale and timing. Neurotransmitters act locally at synapses (nanometer distances) and on millisecond timescales. Hormones travel via bloodstream (whole-body distribution) and act on minute-to-day timescales. The same molecule can be both — norepinephrine is a synaptic transmitter and an adrenal hormone. Neuromodulators (dopamine, serotonin) act at synapses but spread further and longer than classical fast transmitters.
Is the chemical imbalance theory right?
Largely retired. The idea that depression equals low serotonin, schizophrenia equals high dopamine, anxiety equals low GABA was useful 1990s shorthand but oversimplified. Modern view: psychiatric conditions emerge from circuit-level dysregulation, plasticity changes, genetic and environmental interactions. Drugs that change neurotransmitter levels still help many patients; the mechanism likely involves downstream plasticity (e.g., BDNF) rather than direct level correction.